Abbas Basiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abbas Basiri has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
A Firoozan
Urology Nephrology Research Center (UNRC), Labbafi Nejad Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran
1 shared publication- Abolfazl Razzaghdoust
Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Bahram Mofid
Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Behzad Einollahi
Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
1 shared publication - Fatemeh Pour-Reza-Gholi
Department of Nephrology, Labbafinezhad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Hamideh Yadegari
Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany
1 shared publication
Latest Publications
- Open Access
- 2 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Data‐Driven Discovery of Molecular Targets for Antibody‐Drug Conjugates in Cancer Treatment
Antibody‐drug conjugate therapy has attracted considerable attention in recent years. Since the selection of appropriate targets is a critical aspect of antibody‐drug conjugate research and development, a big data research for discovery of candidate targets per tumor type is outstanding and of high interest. Thus, the purpose of this study was to identify and prioritize candidate antibody‐drug conjugate targets with translational potential across common types of cancer by mining the Human Protein Atlas, as a unique big data resource. To perform a multifaceted screening process, XML and TSV files including immunohistochemistry expression data for 45 normal tissues and 20 tumor types were downloaded from the Human Protein Atlas website. For genes without high protein expression across critical normal tissues, a quasi H‐score (range, 0‐300) was computed per tumor type. All genes with a quasi H − score ≥ 150 were extracted. Of these, genes with cell surface localization were selected and included in a multilevel validation process. Among 19670 genes that encode proteins, 5520 membrane protein‐coding genes were included in this study. During a multistep data mining procedure, 332 potential targets were identified based on the level of the protein expression across critical normal tissues and 20 tumor types. After validation, 23 cell surface proteins were identified and prioritized as candidate antibody‐drug conjugate targets of which two have interestingly been approved by the FDA for use in solid tumors, one has been approved for lymphoma, and four have currently been entered in clinical trials. In conclusion, we identified and prioritized several candidate targets with translational potential, which may yield new clinically effective and safe antibody‐drug conjugates. This large‐scale antibody‐based proteomic study allows us to go beyond the RNA‐seq studies, facilitates bench‐to‐clinic research of targeted anticancer therapeutics, and offers valuable insights into the development of new antibody‐drug conjugates.
- 2 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessData‐Driven Discovery of Molecular Targets for Antibody‐Drug Conjugates in Cancer Treatment
Antibody‐drug conjugate therapy has attracted considerable attention in recent years. Since the selection of appropriate targets is a critical aspect of antibody‐drug conjugate research and development, a big data research for discovery of candidate targets per tumor type is outstanding and of high interest. Thus, the purpose of this study was to identify and prioritize candidate antibody‐drug conjugate targets with translational potential across common types of cancer by mining the Human Protein Atlas, as a unique big data resource. To perform a multifaceted screening process, XML and TSV files including immunohistochemistry expression data for 45 normal tissues and 20 tumor types were downloaded from the Human Protein Atlas website. For genes without high protein expression across critical normal tissues, a quasi H‐score (range, 0‐300) was computed per tumor type. All genes with a quasi H − score ≥ 150 were extracted. Of these, genes with cell surface localization were selected and included in a multilevel validation process. Among 19670 genes that encode proteins, 5520 membrane protein‐coding genes were included in this study. During a multistep data mining procedure, 332 potential targets were identified based on the level of the protein expression across critical normal tissues and 20 tumor types. After validation, 23 cell surface proteins were identified and prioritized as candidate antibody‐drug conjugate targets of which two have interestingly been approved by the FDA for use in solid tumors, one has been approved for lymphoma, and four have currently been entered in clinical trials. In conclusion, we identified and prioritized several candidate targets with translational potential, which may yield new clinically effective and safe antibody‐drug conjugates. This large‐scale antibody‐based proteomic study allows us to go beyond the RNA‐seq studies, facilitates bench‐to‐clinic research of targeted anticancer therapeutics, and offers valuable insights into the development of new antibody‐drug conjugates.
- 5 November 2003
- Published by Elsevier in Transplantation Proceedings
- Vol. 35 (7) , 2735-2736
Effect of daclizumab (Zenapax) on prevention of acute rejection of renal transplantation
- 5 November 2003
- Published by Elsevier in Transplantation Proceedings
- Vol. 35 (7) , 2735-2736
Effect of daclizumab (Zenapax) on prevention of acute rejection of renal transplantation